Drug Trial Radar · NCT05999474
Combined Fractional CO2 Laser With Topical Tioconazole Versus Q-switched Nd:YAG Laser in the Treatment of Onychomycosis; a Randomized Controlled Trial
Last checked: Nov 20, 2026Latest source record: Aug 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 1, 2022
Primary completion
Sep 1, 2023
Study completion Oct 1, 2023
Sponsor
- Lead sponsor
- Cairo UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Our aim is to assess the clinical efficacy and the safety of fractional CO2 laser combined with topical tioconazole versus Q-switched Nd:YAG laser in the treatment of OM.
Conditions
- Onychomycosis of Fingernail
Interventions
Topical tioconazoleDrug
Laser
Primary outcomes
What the sponsor says the trial is designed to measure.
- treatment of onychomycosisTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kasr Alainy Faculty of Medicine
Cairo, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.